Contineum Therapeutics, Inc.
CTNM
$9.80
-$0.59-5.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -100.00% | -- |
| SG&A Expenses | 81.99% | 97.89% | 85.18% | 55.92% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.99% | 52.50% | 50.03% | 46.57% | -- |
| Operating Income | -70.99% | -624.55% | -416.57% | -314.36% | -- |
| Income Before Tax | -79.23% | -354.54% | -282.38% | -251.02% | -- |
| Income Tax Expenses | -- | -- | -- | -126.35% | -- |
| Earnings from Continuing Operations | -80.82% | -360.53% | -285.99% | -254.34% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.82% | -360.53% | -285.99% | -254.34% | -- |
| EBIT | -70.99% | -624.55% | -416.57% | -314.36% | -- |
| EBITDA | -71.12% | -613.76% | -411.19% | -310.80% | -- |
| EPS Basic | 69.17% | 0.65% | -445.15% | -246.65% | -- |
| Normalized Basic EPS | 78.14% | -122.43% | -148.03% | -175.26% | -- |
| EPS Diluted | 69.16% | 60.31% | -214.65% | -10.17% | -- |
| Normalized Diluted EPS | 78.14% | -611.05% | -523.21% | -734.99% | -- |
| Average Basic Shares Outstanding | 239.94% | 980.37% | 736.63% | 487.85% | -- |
| Average Diluted Shares Outstanding | 239.94% | 773.76% | 575.35% | 373.69% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |